Drug Trial Radar · NCT07495852
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Feb 17, 2026
Primary completion
Jun 2028
Study completion Mar 2032
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Conditions
- Glaucoma
Interventions
Gen 2 Travoprost Intracameral ImplantDrug
Travoprost
Timolol eye drops 0.5%Drug
Timolol 0.5%
Sham ProcedureProcedure
Sham implant administration
placebo eye dropsOther
Artificial Tears
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular pressure (IOP)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Investigative Site
Dothan, Alabama · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.